Aleix Prat: The prospective real-world clinical impact of HER2DX
Aleix Prat, Director of the Clinic Barcelona Comprehensive Cancer Center, shared a post on LinkedIn about recent paper by Olga Martínez-Sáez et al., titled “Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study” published on ESMO Real World Data and Digital Oncology.
Authors: O. Martínez-Sáez, M. Tapia, M. Marín-Aguilera, E. Hernández-Illán, C. Tébar, A.I. Martinez-Puchol, P. Jares, S. Marín-Liébana, A. Magro, J.A. Puig-Butille, L. Palomar, E. Sanfeliu, M.T. Martinez, M.V. Losada, C. Hernando, B. Adamo, V. Iranzo, T. Pascual, A. Pouptsis, F. Schettini, A. Santaballa, B. Conte, M.D. Torregrosa, F. Brasó-Maristany, B. Walbaum, R. Gómez-Bravo, O. Burgués, I.G. Fructuoso, I. Garrido-Cano, E. Seguí, L. Paré, M. Muñoz, E. Carcelero, J. Sànchez, P. Villagrasa-González, W. Buckingham, A. Prat, G. Villacampa, N. Chic, P. Rivera, A. Rezqallah, C. Saura, S. Escrivà, B. Bermejo, A. Lluch, A. Llombart, J.M. Cejalvo
“New Publication Alert!
Excited to share our latest study published in ESMO Real World Data and Digital Oncology, where we assessed, for the very first time, the prospective real-world clinical impact of HER2DX, a genomic test designed to predict recurrence risk and pathological complete response (pCR) likelihood in 297 patients with early-stage HER2+ breast cancer.
Led by Olga Martínez Sáez, Juan Miguel Cejalvo Andújar, Antonio Llombart Cussac, this study has been conducted across 12 spanish hospitals and have participated 34 medical oncologists.
Key Findings:
- HER2DX led to treatment modifications in nearly 50% of cases, primarily enabling treatment de-escalation.
- The pCR likelihood score was a strong predictor of pCR outcomes, beyond HR status.
- Patients with HER2DX pCR-high disease had similar pCR rates with paclitaxel + dual anti-HER2 blockade as with multi-agent chemotherapy, supporting de-escalation in selected patients.
- Physician confidence in treatment decisions significantly increased after using HER2DX.
- Healthcare costs were reduced by optimizing therapy intensity and minimizing unnecessary treatments.
This study reinforces the clinical utility of HER2DX in guiding personalized treatment decisions, improving patient care, and optimizing healthcare resources.
Read the press release here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023